# Competitive Pipeline Report — Johnson & Johnson

## Executive summary
- Run date (UTC): 2026-01-08
- Source URL: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Stored source PDF: `sources/jnj/2026-01-08.pdf`
- Source SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`
- Programs extracted: 101
- Note: Source PDF unchanged; reused prior snapshot to avoid extraction variability.
- Full inventory export: `reports/jnj/2026-01-08.programs.csv`
- Evidence pack: `reports/jnj/2026-01-08.evidence.json`

**No pipeline update detected**

The pipeline deck appears unchanged versus the last valid snapshot and no pipeline-relevant EDGAR signals were extracted in this run. See corroboration sections for ClinicalTrials.gov and filing coverage.

## Top changes (ranked)
_No ranked changes generated._


## Change log (previous vs current)
### New / Added items
_None detected._

### Removed / Discontinued items
_None detected._

### Phase changes
_None detected._

## ClinicalTrials.gov corroboration
- API base: https://clinicaltrials.gov/api/v2
- Programs with matches: 25/101
- Phase mismatches (pipeline vs registry): 0
- Stored CT.gov evidence: `sources/jnj/ctgov/2026-01-08`

## SEC EDGAR signals
- Filings since: 2026-01-08
- Filings considered: 0
- Filings with extracted events: 0
- Stored EDGAR evidence: `sources/jnj/sec/2026-01-08`

## Pipeline inventory (full list)
| Asset | Indication | Phase | Page | CT.gov phase | Flag |
|---|---|---|---:|---|---|
| AKEEGA (niraparib/abiraterone) | M1 Metastatic Castration-Sensitive Prostate Cancer |  |  | Phase 3 | ok |
| Bleximenib | Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine |  |  | Phase 3 | ok |
| Bleximenib | Relapsed Refractory Acute Myeloid Leukemia |  |  | Phase 3 | ok |
| CABENUVA | HIV Adolescents |  |  |  | none |
| CAPLYTA (lumateperone) | Adjunctive Treatment for Major Depressive Disorder |  |  |  | none |
| CAPLYTA (lumateperone) | Bipolar Mania |  |  |  | none |
| CAPLYTA (lumateperone) | Pediatric Psychiatric Indications |  |  |  | none |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma TNI |  |  |  | ok |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma Transplant Eligible vs ASCT |  |  |  | ok |
| DARZALEX (daratumumab) | Smoldering Multiple Myeloma |  |  | Phase 2 | ok |
| DARZALEX (daratumumab) | Frontline multiple myeloma transplant ineligible |  |  | Phase 2 | ok |
| ERLEADA (apalutamide) | Localized Prostate Cancer |  |  | Phase 2 | ok |
| ERLEADA (apalutamide) | High Risk Prostate Cancer |  |  | Phase 2 | ok |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis |  |  |  | none |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis Pediatrics |  |  |  | none |
| IMBRUVICA (ibrutinib) | Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) |  |  | Phase 2 | ok |
| IMBRUVICA (ibrutinib) | Frontline Mantle Cell Lymphoma |  |  | Phase 2 | ok |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer |  |  |  | none |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer BCG-naïve High Risk |  |  |  | none |
| INLEXZO (gemcitabine intravesical system) | High Risk Non Muscle Invasive Bladder Cancer BGC Experienced |  |  |  | none |
| ITI-1284 | Generalized Anxiety Disorder |  |  |  | none |
| ITI-1284 | Alzheimer's Disease-Related Psychosis |  |  |  | none |
| ITI-1284 | Alzheimer's Disease-Related Agitation |  |  |  | none |
| JNJ-0387 | Solid Tumors |  |  |  | none |
| JNJ-0631 (ARX305) | Renal Cancer |  |  |  | none |
| JNJ-0683 (ARX788) | Breast Cancer |  |  |  | none |
| JNJ-1493 | Hematological Malignancies |  |  |  | none |
| JNJ-1887 sCD59 | Geographic Atrophy |  |  |  | none |
| JNJ-1900 (NBTXR3) | Head and Neck Cancer |  |  |  | none |
| JNJ-1900 (NBTXR3) | Lung Cancer |  |  |  | none |
| JNJ-2056 (tau active immunotherapy) | Alzheimer's Disease |  |  |  | none |
| JNJ-2638 | Gastrointestinal Cancer |  |  |  | none |
| JNJ-2761 | Multiple Myeloma |  |  |  | none |
| JNJ-3413 | Lymphoma |  |  |  | none |
| JNJ-4496 | Hematological Malignancies |  |  |  | none |
| JNJ-4680 | Lung Cancer |  |  |  | none |
| JNJ-4681 | Hematological Malignancies |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Ulcerative Colitis |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Psoriatic Arthritis |  |  |  | none |
| JNJ-4804 Co-antibody Therapy | Crohn's Disease |  |  |  | none |
| JNJ-4916 | Lung Cancer |  |  |  | none |
| JNJ-5108 | Immunological Diseases |  |  |  | none |
| JNJ-5120 | Major Depressive Disorder |  |  |  | none |
| JNJ-5322 | Multiple Myeloma |  |  |  | none |
| JNJ-5939 | Atopic Dermatitis |  |  |  | none |
| JNJ-6420 | Prostate Cancer |  |  |  | none |
| JNJ-6848 | Immunological Diseases |  |  |  | none |
| JNJ-7446 | Lung Cancer |  |  |  | none |
| JNJ-7528 | Atopic Dermatitis |  |  |  | none |
| JNJ-8177 (ARX517) | Prostate Cancer |  |  |  | none |
| JNJ-8377 | Lymphoma |  |  |  | none |
| JNJ-8543 | Hematological Malignancies |  |  |  | none |
| JNJ-9401 | Prostate Cancer |  |  |  | none |
| JNJ-9530 | Hematological Malignancies |  |  |  | none |
| JNJ-9892 | Hematological Malignancies |  |  |  | none |
| JNJ-9968 | Hematological Malignancies |  |  |  | none |
| RPGR Gene Therapy | Retinitis Pigmentosa |  |  |  | none |
| RYBREVANT (amivantamab) | Frontline Non Small Cell Lung Cancer in combination with chemotherapy |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) |  |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) | Colorectal Cancer |  |  | Phase 3 | ok |
| RYBREVANT (amivantamab) | Colorectal Cancer 2L |  |  | Phase 3 | ok |
| SIMPONI (golimumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| SIRTURO | Leprosy |  |  |  | none |
| SIRTURO | Tuberculosis Long Acting |  |  |  | none |
| SPRAVATO (esketamine) | Treatment Resistant Depression monotherapy |  |  |  | none |
| SPRAVATO (esketamine) | Major Depressive Disorder with Suicidal Ideation Pediatrics |  |  |  | none |
| STELARA (ustekinumab) | Pediatric Crohn's Disease |  |  |  | none |
| STELARA (ustekinumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma A-CD38 Naïve |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | TIE NDMM in combination with DR |  |  | Phase 3 | ok |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma |  |  | Phase 3 | ok |
| TAR-210 (RIS/erdafitinib) | Intravesical Delivery System for Localized Bladder Cancer |  |  |  | none |
| TECVAYLI (teclistamab) | Multiple Myeloma 1-3PLs |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | TE NDMM maintenance |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | TIE NDMM in combination with DR |  |  | Phase 3 | ok |
| TECVAYLI (teclistamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  | Phase 3 | ok |
| TREMFYA (guselkumab) | Pediatric Juvenile Psoriatic Arthritis |  |  |  | none |
| TREMFYA (guselkumab) | Pediatric Psoriasis |  |  |  | none |
| TREMFYA (guselkumab) | Psoriatic Arthritis Structural Damage |  |  |  | none |
| TREMFYA (guselkumab) | Ulcerative Colitis Subcutaneous Induction |  |  |  | none |
| TREMFYA (guselkumab) | Pediatric Ulcerative Colitis |  |  |  | none |
| UPTRAVI (selexipag) | Pediatric Pulmonary Arterial Hypertension |  |  |  | none |
| icotrokinra | Psoriasis |  |  |  | none |
| icotrokinra | Psoriatic Arthritis |  |  |  | none |
| icotrokinra | Ulcerative Colitis |  |  |  | none |
| macitentan | Pulmonary Arterial Hypertension 75mg |  |  |  | none |
| milvexian (Factor Xla) | Secondary Stroke Prevention |  |  |  | none |
| milvexian (Factor Xla) | Acute Coronary Syndrome |  |  |  | none |
| milvexian (Factor Xla) | Atrial Fibrillation |  |  |  | none |
| nipocalimab | Warm Autoimmune Hemolytic Anemia |  |  |  | none |
| nipocalimab | Sjogren's Disease |  |  |  | none |
| nipocalimab | Hemolytic Disease of the Fetus and Newborn |  |  |  | none |
| nipocalimab | Fetal and Neonatal Alloimmune Thrombocytopenia |  |  |  | none |
| nipocalimab | Systemic Lupus Erythematosus |  |  |  | none |
| nipocalimab | Idiopathic Inflammatory Myopathy |  |  |  | none |
| nipocalimab | Chronic Inflammatory Demyelinating Polyneuropathy |  |  |  | none |
| pasritamig | Prostate Cancer |  |  | Phase 3 | ok |
| posdinemab | Alzheimer's Disease |  |  |  | none |
| seltorexant | Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms |  |  |  | none |

## Citations / provenance
- Pipeline source: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Stored pipeline PDF: `sources/jnj/2026-01-08.pdf`
- SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`